BIOLOGICAL · Unmapped registry intervention
Certolizumab Pegol
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis
NCT02151851
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Methotrexate
Normalized identity: methotrexateView linked drug · Find medicine records ·
Find other trials using this name
OTHER · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
UCB Pharma SA, Belgiumlead sponsor
Parexelcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02151851 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.